Antibodies

Vanderbilt's James E. Crowe, Jr, MD, and Neil Osheroff, PhD, are among 12 individuals honored by the Association of American Medical Colleges during its 2023 Awards Recognition Event. Read More

Researchers at Vanderbilt University Medical Center and the University of Oxford have determined how a human monoclonal antibody isolated at Vanderbilt in 2021 can prevent infection by the potentially lethal Sin Nombre virus. Read More

Vanderbilt was part of a multi-center team that resurrected a “dead antibody” to reveal the mysteries of cytochrome c, a versatile protein that is an essential part of the cell’s energy-generating capacity, and of life itself. Read More

The U.S. Food and Drug Administration granted emergency use authorization Dec. 8 to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination that protects against COVID-19, discovered last year at Vanderbilt University Medical Center. Read More

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant. Read More

AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca. Read More

Researchers at Vanderbilt University Medical Center have identified antibodies that, in animals, block infection by alphaviruses, which can cause chronic and debilitating joint pain and arthritis and are an increasing global health concern. Read More

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19. Read More

Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months. Read More

Written by Heidi Hall Alpacas aren’t the typical animals that drivers spot as they wind their way through rural Tennessee, but there’s a happy herd of them outside Waverly, where they eat the finest pellets, walk up and down a scenic hill and potentially save lives. They’re owned by… Read More

Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies. Read More

New research links nutrient-responsive cellular signaling to the antibody-mediated immune response. Read More

Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus. Read More

Vanderbilt researchers could be one step closer to finding a way to fight the deadly Ebola virus – thanks to two Ebola victims from Nigeria, who faced death and survived. Vanderbilt researchers developed a unique method of isolating potent Ebola-fighting antibodies from survivors’ blood and they believe these newest… Read More

Vanderbilt University researchers have isolated Ebola-fighting human antibodies – the first of their kind – that could lead to a new treatment for the deadly virus. Read More

Understanding how antibodies with long “loops” form may be important for HIV vaccine development. Read More

New information may help speed development of a vaccine or treatment for dengue fever. Read More

Antibodies to the 2009 H1N1 influenza strain reveal new insights into how antibody diversity forms and functions, with possible implications for designing flu vaccines. Read More